海吉亞醫療(06078.HK)上半年經調整淨利潤2.05億元，同比增加53.1%
格隆匯8月23日丨海吉亞醫療(06078.HK)發佈中期業績公吿，報吿期內，集團營業收入同比增加47.4%至人民幣9.317億元；毛利同比增加45.6%至人民幣3.15億元；非國際財務報吿準則經調整淨利潤同比增加53.1%至人民幣2.052億元；每股基本盈利人民幣0.32元。
於2021年6月30日，集團擁有及經營9家民營營利性醫院，管理2家民營非營利性醫院及向18家醫院合作伙伴就其放療中心提供服務。集團致力向所有患者提供高品質的醫療服務，並將提高患者滿意度放在首位。報吿期內，集團就診患者數量持續增加，門診及住院次均費用穩步提升，促使2021年上半年集團繼續維持增長勢頭，推動收入取得強勁增長。
報吿期內，集團的醫院業務收入為人民幣8.508億元，較上年同期增加53.0%。集團的醫院業務收入由門診醫療服務及住院醫療服務的收入組成，門診醫療服務於期內錄得收入人民幣2.719億元，較上年同期增加70.4%，而住院醫療服務於期內錄得收入人民幣5.789億元，較上年同期增加46.1%。
報吿期內，住院人次為43,833人，較去年同期增加44.3%，門診人次為705,944人，較去年同期增加68.8%。2021年上半年，住院次均收費為人民幣13,207元，較上年同期上漲1.3%，門診次均收費為人民幣385元，較上年同期增加0.8%。截至2021年6月30日，集團經營或管理十一家以腫瘤科為核心的醫院網絡，遍佈中國6個省的7個城市。
展望未來，集團預期將繼續緊緊圍繞腫瘤核心業務，增強品牌影響力。把患者滿意放在首位，不斷提升醫療服務水準、引進前沿的技術及設備以保障醫療服務品質，為腫瘤患者提供覆蓋全生命週期的、一站式的治療服務，用實際行動踐行“讓醫療更温暖”的服務理念；繼續通過標準化的業務板塊和模塊化的管理模式，藉助內生、外延、與第三方合作等方式提高全國範圍內的複製效率，進一步擴大集團在全國的運營網絡及業務規模。
同時，集團將積極引進和培養人才，加強學術建設，積極參與各項國家及省市級的科研項目，鼓勵學術研究及論文發表，加強與高等院校在人才、學術、臨牀領域的合作，推動產、學、研共同發展；通過海吉亞醫療教學研究院，不斷培養具備醫療專業知識的複合型人才，為集團儲備多層次人才梯隊，更好的滿足患者持續增長的要求；進一步遵守行業的各項監管要求，加強規範化運營：落實醫療品質安全核心制度，對醫療品質及醫療安全進行監督，確保醫療安全，增加品牌公信力；進一步鞏固醫院層面的合規意識，嚴格遵循處方開具及醫療保險報銷的有關規定；繼續強化上市公司規範化管理，加強與聯交所等監管機構以及各專業機構的溝通，進一步提升公司的綜合治理水準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
